Next generation processes: What model works the best in Asia?

Presented by

Ravishankar Kasturi, Reliance Life Sciences & Britta Manser ,Scientist Continuous Bioprocessing Pall

About this talk

Next generation processes: What model works the best in Asia? Compare and contrast the available full scale processing technologies, and discover what works the best for manufacturing next generation therapeutic products in Asia. Biologics are complex and hard to make, which helps to explain why biotech manufacturing plants are huge and expensive to build. To be competitive, manufacturing must be efficient and cost-effective and should brainstorm economical ways to manufacture biologics. Biosimilars are a cost competitive market. Pricing may have a direct impact on market share, and return on investment. The market for biologics, including approved and in pipeline like ADCs, antibodies & antibody fragments present both tremendous opportunity and challenge. Challenges necessitates looking beyond the current platform philosophy for how to modify the process with a goal to increase overall productivity in a flexible manner. The current processing paradigm of large manufacturing facilities dedicated to single product production is no longer an effective approach for manufacturing next generation therapeutic products in Asia. Cost Effective Biosimilars Manufacturing may include Single-use technologies and continuous upstream processes have proven to be cost-efficient options Aspects of continuous manufacturing in both upstream and downstream manufacturing are being incorporated thereby increasing yields through a combination of longer production run times, more stable and higher secreting cell lines Technologies enabling high productivity, right-sized, small footprint, continuous, and automated operations are being evaluated. Adaptive control techniques are set to minimize development timelines and enhance process robustness Partnerships will continue to transform biosimilars industry. In order to gain access to developed markets, Indian biosimilar manufacturers are partnering with multiple local established manufacturers and big pharmaceutical companies
Related topics:

More from this channel

Upcoming talks (26)
On-demand talks (368)
Subscribers (36851)
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.